机器人辅助手术在胸部和内脏适应症中的应用:一项更新的系统综述
该系统综述检索了两个数据库(Medline via Ovid 和 The Cochrane Library)2023年4月的文献,限定14种预定义的胸部和内脏手术及随机对照试验(RCT),采用GRADE方法合成关键结局数据,并用Cochrane协作组工具版本1评估偏倚风险。共纳入20项RCT和5篇随访出版物,其中5种手术未找到证据;多数研究未报告或未测量患者相关终点,大多数结局在组间相当,RAS在特定终点(如失血量)显示潜在优势但基于少量低质量研究,在特定适应症的复发、生活质量、输血和住院方面观察到统计学显著的RAS获益,机器人辅助胃切除术、直肠和肝脏切除术的安全结局改善,手术时间结果矛盾。结论指出,由于不同结局和手术的低质量证据不一致且不足,无法就RAS优越性做出确定性断言。
要点
- 共纳入20项RCT和5篇随访出版物,14种手术中5种未找到证据。
- 多数研究未报告或未测量患者相关终点,大多数结局组间相当。
- RAS在失血量等特定终点显示潜在优势,但基于少量低质量研究。
核心结论
- 由于不同结局和手术的低质量证据不一致且不足,无法就RAS优越性做出确定性断言。
- RAS可能在某些手术领域提供潜在优势,但医疗决策还应考虑证据质量有限、经济影响和环境因素,并扩展到人体工程学方面以维持健康的手术环境。
研究设计与样本
- 系统综述,检索Medline via Ovid和The Cochrane Library两个数据库2023年4月的文献。
- 检索限定于14种预定义的胸部和内脏手术及随机对照试验(RCT)。
- 采用GRADE方法合成关键结局数据,使用Cochrane协作组工具版本1评估偏倚风险。
- 共纳入20项RCT和5篇随访出版物。
主要发现
- 14种手术中5种未找到证据。
- 多数研究未报告或未测量患者相关终点,大多数结局组间相当。
- RAS在特定终点(如失血量)显示潜在优势,但基于少量低质量研究。
- 在特定适应症的复发、生活质量、输血和住院方面观察到统计学显著的RAS获益。
- 机器人辅助胃切除术、直肠和肝脏切除术的安全结局改善;手术时间结果矛盾。
关键数值与推荐
- 纳入标准限定为14种预定义的胸部和内脏手术及RCT。
- 证据质量采用GRADE方法评估,偏倚风险采用Cochrane协作组工具版本1评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 多数研究未报告或未测量患者相关终点。
- RAS在特定终点的潜在优势基于少量低质量研究。
- 不同结局和手术的低质量证据不一致且不足,阻碍确定性断言。
- 手术时间结果矛盾。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In surgical advancements, robot-assisted surgery (RAS) holds several promises like shorter hospital stays, reduced complications, and improved technical capabilities over standard care. Despite extensive evidence, the actual patient benefits of RAS remain unclear. Thus, our systematic review aimed to assess the effectiveness and safety of RAS in visceral and thoracic surgery compared to laparoscopic or open surgery. METHODS: We performed a systematic literature search in two databases (Medline via Ovid and The Cochrane Library) in April 2023. The search was restricted to 14 predefined thoracic and visceral procedures and randomized controlled trials (RCTs). Synthesis of data on critical outcomes followed the Grading of Recommendations, Assessment, Development, and Evaluation methodology, and the risk of bias was evaluated using the Cochrane Collaboration's Tool Version 1. RESULTS: For five out of 14 procedures, no evidence could be identified. A total of 20 RCTs and five follow-up publications met the inclusion criteria. Overall, most studies had either not reported or measured patient-relevant endpoints. The majority of outcomes showed comparable results between study groups. However, RAS demonstrated potential advantages in specific endpoints (e.g., blood loss), yet these findings relied on a limited number of low-quality studies. Statistically significant RAS benefits were also noted in some outcomes for certain indications-recurrence, quality of life, transfusions, and hospitalisation. Safety outcomes were improved for patients undergoing robot-assisted gastrectomy, as well as rectal and liver resection. Regarding operation time, results were contradicting. CONCLUSION: In summary, conclusive assertions on RAS superiority are impeded by inconsistent and insufficient low-quality evidence across various outcomes and procedures. While RAS may offer potential advantages in some surgical areas, healthcare decisions should also take into account the limited quality of evidence, financial implications, and environmental factors. Furthermore, considerations should extend to the ergonomic aspects for maintaining a healthy surgical environment.
引用
- Grössmann-Waniek N, Riegelnegg M, Gassner L, et al. Robot-assisted surgery in thoracic and visceral indications: an updated systematic review. Surg Endosc. 2024. PMID: 38307958. doi:10.1007/s00464-023-10670-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。